<DOC>
	<DOC>NCT00109109</DOC>
	<brief_summary>The purposes of this study are: - To determine the maximum tolerated dose (MTD) of SAHA administered every 12 hours for 14 consecutive days followed by 7 days of rest during the first two cycles (i.e., first 6 weeks) in patients with advanced multiple myeloma; - To assess the safety and overall response rate to SAHA in patients with advanced multiple myeloma.</brief_summary>
	<brief_title>A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Adult patients with refractory or relapsed multiple myeloma, ECOG performance status 02 (ECOG) Adequate bone marrow reserve Adequate hepatic and renal function Ability to swallow capsules 3 weeks or more from prior chemotherapy and have recovered from prior toxicities Patients who plan to go for bone marrow transplant within 4 weeks of start of treatment Patients with prior treatment with other investigational agents with a similar antitumor mechanism Patients with other active/uncontrolled clinically significant illnesses Pregnant or nursing female patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>